Swiss Rockets secured an exclusive global license (excluding Asia‑Pacific for now) to CoolMPS chemistry from MGI Tech and Complete Genomics, aiming to develop and commercialize CoolMPS‑based next‑generation sequencers as early as next year. The company plans to rely on Complete Genomics’ manufacturing expertise to accelerate product development and market entry. Swiss Rockets framed the license as a strategic move to position a Swiss company as a Western alternative for CoolMPS‑based instruments, citing geopolitical and commercial advantages in Europe and the U.S. The deal includes options to expand rights to Asia‑Pacific in 2026. Market participants will evaluate whether Swiss Rockets can execute instrument development and service offerings quickly enough to challenge incumbent sequencing platforms and how customers will respond to another entrant in an already competitive NGS instrumentation market.